What does mTSS stand for?

Results from the open-label extension study to RAPID 1 met both co-primary endpoints (American College of Rheumatology (ACR) 20 response(a) scores at Week 24 and change from baseline in modified Total Sharp Scores at Week 52).

RAPID 1 achieved its co-primary endpoint, the inhibition of progression of structural damage, with a statistically significantly smaller change from baseline in modified Total Sharp Score (mTSS)(a) observed at week 52 in both CIMZIA(TM) treatment arms (400mg at week zero, week two and week four followed by 200mg every two weeks; or 400mg every two weeks) compared with the placebo treated arm (p<0.

The mean change in the modified total Sharp score in patients who had both baseline and week 24 radiographs was -0.

RAPID 1 achieved its co-primary endpoint, the inhibition of progression of structural damage, with a statistically significantly smaller change from baseline in modified Total Sharp Score (mTSS)(a) observed at week 52 in both CIMZIA(TM) treatment arms (400mg at week zero, week two and week four followed by 200mg every two weeks; or 400mg every two weeks) compared with the placebo treated arm (p<0.

At week 24, modified Total Sharp Scores (mTSS), a measurement used to assess changes in bone erosion and joint-space narrowing, showed that approximately three times as many patients receiving placebo had an increase in their scores (increase in mTSS >0.

Modified Total Sharp Score assesses bone erosion and joint space narrowing on X-rays.

The study's second primary endpoint examined the change in modified Total Sharp Score (mTSS), a measurement used to assess changes in bone erosion and joint-space narrowing in X-rays, at week 24.

The study's second primary endpoint examined the change in modified Total Sharp Score (mTSS), a measurement used to assess changes in bone erosion and joint-space narrowing, at week 24.